Rasna Therapeutics has announced the appointment of Dr. Kunwar Shailubhai as Chief Executive Officer.
Dr. Shailubhai was a co-founder and served as the Chief Scientific Officer and prior Senior Vice President, Drug Discovery, of Synergy Pharmaceuticals Inc from 2004, where he led the development of Trulance™ from inception to FDA approval, having co-invented and pioneered Synergy’s platform technology surrounding the therapeutic applications of guanylate cyclase C agonists for functional GI disorders, inflammatory bowel disease, GI cancer, cholesterol lowering, asthma and other lung diseases.
Between 1993 and 2000, he served as Research Specialist and Group Leader of the cancer chemoprevention group at Monsanto Company. Dr. Shailubhai also previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor of Research at the University of Maryland.
Dr. Shailubhai received his PhD in microbiology from the University of Baroda, India, and his MBA from the University of Missouri, St. Louis. He has more than 20 issued patents and over 40 peer-reviewed publications.
Dr. Alessandro Padova, Chairman of Rasna Therapeutics, said: “We are delighted to welcome Kunwar into this role. He brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialisation to market.”